LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) today announced the appointments of Charles A. Dinarello, M.D., professor of medicine at the University of Colorado School of Medicine, and Edward Roberts, Ph.D., professor of translational chemistry and medicine at The Scripps Research Institute, to the company’s Scientific Advisory Board (SAB). Dr. Dinarello is a world-leading expert on preclinical and clinical studies of inflammatory cytokines, particularly interleukin-1 and related cytokines. Cytokines regulate inflammation and are involved in a variety of immunological, inflammatory and infectious diseases. Dr. Roberts is a world-renowned chemist with more than 30 years of drug development experience at both large pharmaceutical and biotech companies specializing in the treatment of disorders of the central nervous system. The EPIX SAB was established to advise the company on key aspects of the clinical development programs for its therapeutic drug candidates.
